Effect of probiotic strains of escherichia and enterococci on activities of intestinal digestive enzymes at correction of experimental dysbiosis in rats

In experiments on Wistar rats, the effects of probiotic bacteria Enterococcus faecium L3 and Escerichia coli M17 on the restoration of the microbiota and activities of the intestinal digestive enzymes after experimental dysbiosis were compared. Dysbiosis was caused by intragastric administration of ampicillin and metronidazole for 3 days. Subsequently, probiotics containing E. faecium L3 (E. f.) and E. coli M17 (E. c.), or milk (control-1, K1) were administered to the animals intragastrically for 5 days. In the control K0, rats were given water, instead of antimicrobials, and then milk. Activities of the enzymes in the small intestinal mucosa were evaluated by biochemical methods, and the microbiota composition - bacteriologically and by PCR in real time. After using the E. f. there was a faster recovery of the intestinal microbiota than after using the E. c. or without probiotics (in the group K1). In the group K1, the activity of maltase, lactase, alkaline phosphatase and aminopeptidase N in the small intestine was increased in comparison with the control K0 (without antimicrobial agents and probiotics). Use of the E. f. and E. c. did not affect a recovery of the activity of aminopeptidase N, but was accompanied by a partial restoration of alkaline phosphatase activity and a tendency to restore maltase activity, and in the case of the E. f. a complete recovery of lactase activity was also observed. Thus, the probiotic E. faecium L3 bacteria, compared to the E. coli M17, are more effective in restoring the microbiota and the activity of some key intestinal enzymes (in particular lactase) after the disorders caused by intestinal dysbiosis.

Enterococcus faecium L3, Escherichia coli M17, intestine, digestive enzymes, microbiota, Enterococcus faecium L3, Escherichia coli M17

1. Уголев А.М. Теория адекватного питания и трофология. // А.: Наука. - 1991. - 272 с.

2. Шендеров Б. А. Медицинская микробная экология и функциональное питание. // М.: Издательство Грантъ. - 1998. - Т. 1 (Микрофлора человека и животных и ее функция). - 288 с.

3. Ткаченко Е.И., Успенский Ю.П. Питание, микробиоценоз и интеллект человека. // СПб. - 2006. - 560 с.

4. Cani P. D., Delzenne N. M. The role of the gut microbiota in energy metabolism and metabolic disease. // Current Pharmaceutical Design. - 2009. - Vol. 15. - P. 1546-1558.

5. Goldin B. R., Gorbach S. L. Clinical indication for probiotics; An Overview. // Clinical Infectious D'iseases. - 2008. - Vol. 46. - Р. 96-100.

6. Громова А.В., Алексеева А.С., Дмитриева Ю.В., Савочкина Е.В., Груздков А.А., Котылева М.П., Ермоленко Е.И., Суворов А.Н. Влияние пробиотических бактерий на пищеварение в кишечнике при коррекции экспериментального дисбиоза у крыс // Медицинский алфа-вит. - 2017. - Т. 1 (Практическая гастроэнтерология), № 9. - С. 46-49.

7. Ermolenko E., Gromova L., Borshchov Yu., Voeikova A., Karaseva A., Ermolenko K., Gruzdkov A., Suvorov A. Influence of different probiotic lactic acid bacteria on microbiota and metabolism of rats with disbiosis. // Bioscience of Microbiota, Food and Health. - 2013. - Vol. - 32, № 2. - P. 41-49.

8. Ермоленко Е.И., Донец В.Н., Дмитриева Ю.В., Ильясов Ю.Ю., Суворова М.А., Громова А.В. Влияние пробиотических энтерококков на функциональные характеристики кишечника крыс при дисбиозе, индуцированном антибиотиками. // Вестник Санкт-Петербургского университета. Серия 11. Медицина. - 2009. Вып. № 1. - C. 157-167.

9. Тимофеева Н.М. Иезуитова Н.Н., Громова А.В. Современные представления о всасывании моносахаридов, аминокислот и пептидов в тонкой кишке млекопитающих. // Успехи физиологических наук. - 2000. - Т. 31, № 4. - С. 24-37.

10. Lin A.H., Nichols B.L., Quezada-Calvillo R., Avery S.E., Sim L., Rose D.R., Naim H.Y., Hamaker B.R. Unexpected high digestion rate of cooked starch by the Ct-maltase-glucoamy-lase small intestine mucosal a-glucosidase subunit // PLos One. - 2012. - V. 7, № 5; e35473.

11. Lallès J.P. Intestinal alkaline phosphatase; novel functions and protective effects // Nutr. Rev. - 2014. - Vol. 72, № 2. - P. 82-94.

12. Tuin A., Poelstra K., de Jager-Krikken A. et al. Role of alkaline phosphatase in colitis in man and rats 11 Gut, 2009. - V. 58, № 3. - P. 379-387.

13. Estaki M., DeCoffe D., Gibson D.L. Interplay between intestinal alkaline phosphatase, diet, gut microbes and immunity // World J. Gastroenterol. - 2014. - Vol. 20, № 42. - P. 15650-15656.

14. Kramer W., Girbig F., Corsiero D., Pfenninger A., Frick W.et al. Aminopeptidase N (CD 13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane // J. Biol. Chem. - 2005. - Vol. 280, № 2. P. - 1306-1320.

15. Melkebeek V., Rasschaert K., P Bellot P., Tilleman K., Favoreel H., et al. Targeting aminopeptidase N, a newly identified receptor for F4ac fimbriae, enhances the intestinal mucosal immune response // Mucosal Immunol. - 2012. - Vol. 5, № 6. - P. 635-645.

16. Bank U., Tadje M., Wolke C., Bukowska A., Ittenson A., et al. Inhibition of alanyl-aminopeptidase on CD4+CD25+ regulatory T-cells enhances expression of FoxP3 and TGF-beta1 and ameliorates acute colitis in mice.// Int. Mol. Med. - 2007, Oct. - Vol. 20, № 4. - P. 483-492.